---
title: Nurse Intervention Trial
nct_id: NCT06200480
overall_status: TERMINATED
phase: NA
sponsor: Norwegian University of Science and Technology
study_type: INTERVENTIONAL
primary_condition: Migraine
countries: Norway
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06200480.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06200480"
ct_last_update_post_date: 2026-04-13
last_seen_at: "2026-05-12T06:12:57.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Nurse Intervention Trial

**Official Title:** Nurse Intervention Trial: The Evaluation of Usefulness of a Headache Nurse

**NCT ID:** [NCT06200480](https://clinicaltrials.gov/study/NCT06200480)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Based on ethical considerations arising from the interim analyses, the study was terminated before the planned sample size of 400 participants was reached
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 147
- **Lead Sponsor:** Norwegian University of Science and Technology
- **Collaborators:** Haukeland University Hospital, Oslo University Hospital, St. Olavs Hospital
- **Conditions:** Migraine, Chronic Tension-Type Headache, Cluster Headache, Hemicrania Continua
- **Start Date:** 2023-04-21
- **Completion Date:** 2026-01-31
- **CT.gov Last Update:** 2026-04-13

## Brief Summary

This randomized open-label prospective study focus on headache patients initiating preventive treatment, where the treating physician identifies a need for follow-up visits in specialized healthcare. The study will clarify whether the implementation (compliance) and overall satisfaction of the patient are better with follow-up by a headache nurse compared to standard follow-up. Patients with signed written consent will be randomised to either group a: Telephone calls from nurse after two and 6 week or B. Patient-initiated follow-up by their general practitioner.

## Detailed Description

Potential patients suitable for this study must have undergone a regular consultation with a neurologist before. This consultation includes neurological and somatic examinations, diagnosis of the type of headache based on medical history, review of a completed headache diary, and any additional conducted examinations. The consultation will also involve an assessment of the possible initiation of preventive treatment. A selection of these patients will be prescribed electronic prescriptions for at least one previously untried type of preventive medication. During the consultation, patients will receive oral and written information about the dosage and expected possible side effects of the preventive medication. Those eligible for beta-blocker initiation will undergo an electrocardiogram (EKG) after the consultation. After completing the consultation, eligible patients will receive written and oral information about the study.

Those who provide consent to participate will, during subsequent registration with the secretaries at the neurological outpatient clinic immediately after the consultation, be randomized to one of two follow-up options (A or B) for further monitoring in the coming months until the scheduled follow-up, set at approximately 3 months, or later if there is a shortage of available appointments.

Group A will be followed up by a headache nurse through telephone consultations on at least two occasions shortly after the initiation of preventive medicine. Participants in this group will be invited to a planned final follow-up appointment after approximately 3 months with a neurologist.

Group B will have patient-managed follow-up with a planned final follow-up appointment after approximately 3 months. Participants will pick up the prescribed medication and contact their general practitioner or the neurological outpatient clinic by a study-specific email if they need advice from a neurologist.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 90 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* One of the following headache diagnoses based on the International Classification of Headache Disorders, third edition (ICDH3): G44.2 Chronic tension-type headache and/or G43 Episodic and chronic migraine, G44.0 Episodic and chronic cluster headache, G44.8 Hemicrania Continua
* Indication for preventive medication where there is at least one alternative with the need for follow-up assessment of effectiveness.

Exclusion Criteria:

* Uncertain headache diagnosis.
* Need further investigation after the initial consultation.
* Lack of understanding of information provided in Norwegian, both verbally and in writing.
* Inability to keep a digital headache diary.
* Need treatment of other comorbid conditions requiring follow-up in specialized healthcare.
* Treatment with Onabotulinumtoxin A or Calcitonin-gene-related Peptide (CGRP) inhibitors given with three months intervals
```

## Arms

- **Telephone by nurse** (ACTIVE_COMPARATOR) — The headache patients will be contacted by nurse by phone after approximately 2 week and 6 week after start of preventive medical treatment. The patient will have a follow-up visit by neurologist after 3 months.
- **Patient-initiated follow-up** (NO_INTERVENTION) — The headache patient contact their general practitioner (GP) and/or the neurologist by a study-specific email if they have questions regarding the preventive medical treatment

## Interventions

- **Telephone by nurse** (OTHER) — Patient-initiated follow-up at week 2 and 6

## Primary Outcomes

- **Compliance** _(time frame: 2 months)_ — number of participants who have carried out the prescribed preventive treatment, as in minimum duration of two months after the initial visit

## Secondary Outcomes

- **Number of days to at least a 30% reduction** _(time frame: 3 months)_
- **Responders** _(time frame: 3 months)_

## Locations (1)

- St. Olavs Hospital HF, Trondheim, Norway

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.st. olavs hospital hf|trondheim||norway` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06200480.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06200480*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*